DENKA SEIKEN CO., LTD. Patent applications |
Patent application number | Title | Published |
20160116481 | PREPARATION OF VISIBLE COLORED INSOLUBLE CARRIER PARTICLES LABELED WITH A FLUORESCENT DYE AND AN IMMUNOASSAY METHOD USING THE SAME - The object of the present invention is to provide insoluble carrier particles used for high-sensitivity rapid immunoassay, which allow visual observation and high-sensitivity apparatus measurement. | 04-28-2016 |
20160041161 | TEST KIT - The present invention provides a test kit capable of rapid and highly sensitive detection. | 02-11-2016 |
20160003810 | A METHOD FOR ESTIMATING GFR (GLOMERULAR FILTRATION RATE) FROM MEASURED VALUE OF MEGALIN IN URINE - The object of the present invention is to provide a method for estimating the glomerular renal function in a convenient and non-invasive manner. As a result of intensive studies to achieve the above object, the present inventors found that there is a high correlation between the urinary megalin excretion rate and the estimated glomerular filtration rate (eGFR) in renal disease patients, and the glomerular filtration rate (GFR) can be estimated with high probability in a non-invasive manner by measuring the megalin level in the urine. This has led to the completion of the present invention. | 01-07-2016 |
20150369799 | METHOD FOR SUPPRESSING FALSE NEGATIVE IN IMMUNOASSAY FOR DERIVED FROM BIOLOGICAL MUCOUS MEMBRANE - The problem to be solved is accurately and specifically detecting a target substance by suppressing the action of an immunoassay inhibitory substance contained in a specimen derived from a biological mucous membrane. A false negative can be suppressed by treating a specimen with a specimen treatment solution containing a compound having two or more sulfate groups in immunoassay for analyzing a target substance in a specimen derived from a biological mucous membrane. | 12-24-2015 |
20150285791 | METHOD FOR INCREASING THE SENSITIVITY OF IMMUNOASSAY SYSTEM THROUGH PRETREATMENT OF URINE WITH DENATURANT - An object of the present invention is to provide a method for increasing the sensitivity of an immunoassay system. In order to achieve the object, the present inventors have discovered that the sensitivity of an immunoassay system can be increased by pretreating urine and thus have completed the present invention. | 10-08-2015 |
20150233922 | METHOD FOR MEASURING HEMAGGLUTININ FROM INFLUENZA VIRUS - Disclosed is a novel method for measuring haemagglutinin of an influenza virus, which can construct an assay system in a shorter period of time than a sandwich immunoassay method using two kinds of anti-haemagglutinin antibodies. The method for measuring haemagglutinin of an influenza virus is achieved by a sandwich immunoassay method comprising sandwiching the haemagglutinin between a lectin which binds to the haemagglutinin but does not bind to an antibody, and an anti-haemagglutinin antibody which undergoes antigen-antibody reaction with the haemagglutinin. | 08-20-2015 |
20150132834 | METHOD FOR REMOVAL OF TRIGLYCERIDES IN LIPOPROTEINS OTHER THAN LOW-DENSITY LIPOPROTEINS - Disclosed is a method for selectively eliminating triglycerides in lipoproteins other than low density lipoprotein, which method allows one to provide a method for directly and differentially quantifying LDL-TG in a sample with excellent simplicity, specificity and accuracy using an automated analyzer or the like without performing a laborious operation of pretreatment such as centrifugation or electrophoresis. The method for eliminating triglycerides in lipoproteins other than low density lipoproteins includes allowing lipoprotein lipase, cholesterol esterase, glycerol kinase and glycerol-3-phosphate oxidase to act on a sample in the presence of a surfactant that acts on lipoproteins other than low density lipoprotein and/or a surfactant having LDL-protecting action, and eliminating hydrogen peroxide produced thereby. | 05-14-2015 |
20150086975 | IMMUNOLOGICAL ANALYSIS METHOD AND REAGENT - Disclosed are an immunoassay method which can measure an antigen with high sensitivity and accuracy; and a reagent therefor. In the immunoassay method, an antigen-antibody reaction and/or a measurement is(are) carried out in the presence of a polycarboxylic acid type surfactant. The immunoassay reagent for use in the method is characterized by comprising the polycarboxylic acid type surfactant. By employing such a simple means that the polycarboxylic acid type surfactant is allowed to be present in the reaction and/or measurement system, non-specific reactions can be suppressed effectively even in a highly sensitive immunoassay, and an antigen can be measured accurately and specificity can be improved in the immunoassay. | 03-26-2015 |
20150079616 | METHOD FOR QUANTIFYING SUBFRACTION OF CHOLESTEROL (-C) IN HIGH-DENSITY LIPOPROTEIN (HDL) - Provided is a method for separately or simultaneously quantifying whole HDL-C and cholesterol in HDL subfractions: ApoE-Containing HDL-C and ApoE-deficient HDL-C. A method for enzymatically and separately quantifying cholesterol in the ApoE-deficient HDL comprising: adding a surfactant composed of a polyoxyethylene benzyl phenyl ether derivative to a test sample in a final concentration of 0.05 to 0.10%, reacting the test sample with cholesterol esterase and cholesterol oxidase, and quantifying hydrogen peroxide generated. A method for enzymatically and separately quantifying cholesterol in ApoE-Containing HDL comprising: adding a surfactant composed of a polyoxyethylene benzyl phenyl ether derivative so as to obtain a final concentration of 0.15 to 0.75%, reacting the test sample with cholesterol esterase and cholesterol oxidase, and quantifying hydrogen peroxide generated. | 03-19-2015 |
20150044774 | METHOD FOR QUANTIFYING CHOLESTEROL IN HIGH DENSITY LIPOPROTEIN 3 - Disclosed is the provision of a method for quantifying HDL3 in a test sample without requiring a laborious operation. The method for quantifying cholesterol in high-density lipoprotein 3 comprises allowing a surfactant(s) which specifically react(s) with a high-density lipoprotein 3 to react with a test sample and quantifying cholesterol, and the surfactant(s) is(are) at least one selected from the group consisting of polyoxyethylene polycyclic phenyl ether and polyoxyethylene styrenated phenyl ether. | 02-12-2015 |
20150031052 | METHOD FOR REDUCING ADSORPTION OF BUBBLES - Provided is a means for improving measurement accuracy in an immunoassay using a dry plastic cell. A method for reducing adsorption of bubbles onto a cell side surface in an immunoassay, the method including carrying out a reaction and/or measurement in a presence of a surfactant, wherein the immunoassay comprises carrying out an antigen-antibody reaction in a dry plastic cell using an immunoassay reagent which immunologically reacts with a substance to be measured in a sample and carrying out an optical measurement of a resultant reacted product. | 01-29-2015 |
20140349277 | ANTI-HUMAN NOROVIRUS GII ANTIBODY - Provided is an anti-human-norovirus GII antibody which responds to substantially all genotypes of the human noroviruses belonging to GII and which can comprehensively detect such human noroviruses GII. | 11-27-2014 |
20140045201 | METHOD FOR QUANTIFYING CHOLESTEROL IN HIGH-DENSITY LIPOPROTEIN 2, AND REAGENT KIT FOR THE METHOD - Disclosed is a method for quantifying HDL2 cholesterol in a test sample without requiring laborious operations. The method for quantifying cholesterol comprises allowing phospholipase to act on HDL to quantify cholesterol. Also disclosed is a method comprising: a first step of transferring cholesterols other than high-density lipoproteins in a test sample to the outside of the reaction system; and a second step of quantifying high-density lipoprotein 2 cholesterol among the high-density lipoproteins remaining in the reaction system; wherein, by performing the second step by the above method, high-density lipoprotein 2 cholesterol in the test sample can be quantified. | 02-13-2014 |
20130302907 | METHOD OF ASSAYING ANTIGEN AND REAGENT THEREFOR - A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range. The large sensitized latex particles and the small sensitized latex particles are reacted with the test antigen in the state suspended in a buffer, and then the agglutination of the sensitized latex particles is optically measured. | 11-14-2013 |
20130230873 | METHOD FOR QUANTIFICATION OF REMNANT-LIKE LIPOPROTEIN CHOLESTEROL AND KIT FOR SAME - A method for quantifying remnant-like lipoprotein cholesterol in a sample simply and accurately without requiring separation operations, and a kit therefor are disclosed. A method for quantifying cholesterol in a remnant-like lipoprotein in a sample containing different lipoproteins including the remnant-like lipoprotein comprises a step (1) of erasing cholesterol in lipoproteins other than the remnant-like lipoprotein; and a step (2) of quantifying cholesterol in the remaining remnant-like lipoprotein. The step (1) is carried out under an action of a cholesterol esterase having a molecular weight of more than 40 kDa and not having a subunit having a molecular weight of not more than 40 kDa; and the step (2) is carried out under an action of a cholesterol esterase having a molecular weight of not more than 40 kDa or a cholesterol esterase having a subunit having a molecular weight of not more than 40 kDa. | 09-05-2013 |
20130171674 | METHOD FOR QUANTIFYING THE AMOUNT OF CHOLESTEROL IN HIGH-DENSITY LIPOPROTEIN 3 - A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and/or sphingomyelinase is/are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample. | 07-04-2013 |
20130164769 | METHOD FOR QUANTIFYING THE AMOUNT OF CHOLESTEROL IN HIGH-DENSITY LIPOPROTEIN 3 - A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises reacting, with a test sample, a surfactant that specifically reacts with high-density lipoprotein 3, and quantifying cholesterol. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample. | 06-27-2013 |
20130157374 | METHOD FOR QUANTIFYING THE AMOUNT OF CHOLESTEROL IN HIGH-DENSITY LIPOPROTEIN 3 - A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein a surfactant that reacts with lipoproteins other than high-density lipoprotein 3 is reacted with a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample. | 06-20-2013 |
20120322087 | METHOD FOR EXAMINING ACUTE RENAL DISORDER - Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful. | 12-20-2012 |
20120208219 | METHOD FOR ASSAYING CHOLESTEROL IN ApoE-CONTAINING HDL - This invention provides a method for separately or simultaneously quantifying cholesterol in a total amount of HDL-C, cholesterol in an HDL subfraction of apoE-containing HDL-C, and cholesterol in an HDL subfraction of apoE-deficient HDL-C. The method comprises enzymatically and separately quantifying cholesterol in apoE-containing HDL and cholesterol in apoE-deficient HDL by adding a surfactant selected from the group consisting of a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of 0.7 to less than 1.3, a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of less than 0.7, and a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of 1.3 or more to a test sample, allowing cholesterol esterase and cholesterol oxidase to react therewith, and quantifying the hydrogen peroxide generated. | 08-16-2012 |
20120164667 | METHOD FOR TEST ON DIABETIC NEPHROPATHY - Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin. | 06-28-2012 |
20120164662 | TEST METHOD ON RENAL DISEASES - Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly. | 06-28-2012 |
20120142054 | SRSV DETECTION KIT - A polynucleotide base sequence represented by SEQ ID NO: 22, a vector containing the polynucleotide and a method of preparing a small round structure virus (SRSV) virus-like particle in insect cells with vector. | 06-07-2012 |
20120107957 | TEST REAGENT, AND METHOD FOR MEASURING ANALYTE IN TEST SAMPLE USING SAME - Object: To provide a test reagent for the analyte in a test sample, utilizing the level of agglutination of a particle suspension which suspend insoluble carrier particles carrying a substance for capturing the analyte as an indicator, which reagent does not undergo self-agglutination during storage, and which non-specific agglutination rarely occurs during measurement, as well as to provide a method for the analyte to be measured in a test sample. Means for Solution: The test reagent for the analyte comprises at least a Solution A which is a buffer solution having an electric conductivity of not less than 30 ms/cm; and a Solution B having an electric conductivity of not more than 6.5 ms/cm, the Solution B being a particle suspension which suspends particles which are insoluble carrier particles carrying a substance for capturing the analyte. | 05-03-2012 |
20120077261 | DEVICE FOR A MEMBRANE ASSAY - Disclosed is a simple device for a membrane assay using the lateral flow immunoassay method, whereby a subject to be detected can be detected at a high sensitivity, provided with, as a label drying pad, a substrate which has a higher tensile strength than glass fiber and can well release a label. The present invention provides a simple membrane assay device, comprising: a supporting board, a sample supply part, a label containing a labeling component which labels a subject to be detected, a development part formed with a detection part which includes a trapping reagent for detecting or quantifying the subject to be detected, and an absorption part, wherein a non-woven fabric which includes fibers having a fiber diameter of 0.05 to 10 μm is used in the labeling component part. | 03-29-2012 |
20120058489 | USE OF MEGALIN IN URINE AS MARKER FOR DETECTING RENAL DISORDER - This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder. | 03-08-2012 |
20110223614 | TOXIN DETECTION METHOD - According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in | 09-15-2011 |
20110195523 | METHOD FOR MEASURING HUMAN MEGALIN - This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed. | 08-11-2011 |
20110143458 | TEST DEVICE FOR MEMBRANE ASSAY COMPRISING REFERENCE DISPLAY SECTION - A test device provided with a reference display section that rapidly and clearly indicates proper test completion with improved accuracy and stability is provided. Such test device is a test device for membrane assay using a specific binding reaction of a substance to be detected with a capture reagent immobilized on a membrane carrier and a reagent labeled with a labeling substance, which comprises a reference display section for indicating proper test completion on which a cationic polymer for capturing a labeled reagent has been immobilized. | 06-16-2011 |
20110081731 | Method of Assaying Antigen and Reagent Therefor - A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range. The large sensitized latex particles and the small sensitized latex particles are reacted with the test antigen in the state suspended in a buffer, and then the agglutination of the sensitized latex particles is optically measured. | 04-07-2011 |
20100216257 | Method of Assaying Antigen and Reagent Therefor - A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range. The large sensitized latex particles and the small sensitized latex particles are reacted with the test antigen in the state suspended in a buffer, and then the agglutination of the sensitized latex particles is optically measured. | 08-26-2010 |
20100092487 | TOXIC DETECTION METHOD - According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in | 04-15-2010 |
20090305420 | SRSV DETECTION KIT - This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related virus constituting peptides selected from the following peptide groups (a) to (k), respectively: (a) a peptide having an amino acid sequence represented by SEQ ID NO: 1, and the like, (b) a peptide having an amino acid sequence represented by SEQ ID NO: 2, and the like, (c) a peptide having an amino acid sequence represented by SEQ ID NO: 3, and the like, (d) a peptide having an amino acid sequence represented by SEQ ID NO: 4, and the like, (e) a peptide having an amino acid sequence represented by SEQ ID NO: 5, and the like, (f) a peptide having an amino acid sequence represented by SEQ ID NO: 6, and the like, (g) a peptide having an amino acid sequence represented by SEQ ID NO: 7, and the like, (h) a peptide having an amino acid sequence represented by SEQ ID NO: 8, and the like, (i) a peptide having an amino acid sequence represented by SEQ ID NO: 9, and the like, (j) a peptide having an amino acid sequence represented by SEQ ID NO: 10, and the like, and (k) a peptide having an amino acid sequence represented by SEQ ID NO: 11, and the like. | 12-10-2009 |
20090286226 | Simple membrane assay method and kit - A simple membrane assay method for detecting or quantitating an analyte in a specimen sample using an assay device equipped with a membrane bound with a capture-substance to capture the analyte, including the steps of filtering a specimen sample using a filter, dropping the filtrate onto said membrane and detecting the presence of the analyte in said specimen sample, as well as a simple membrane assay kit for detecting the presence of an analyte in a specimen sample, including (1) a filter tube, and (2) an assay device equipped with a membrane bound with a capture-substance to capture the analyte. The method or the kit can decrease the occurrence of false positivity and can provide a highly accurate detection of the analyte such as pathogen and antibody in a specimen collected in a medical scene or by an individual. | 11-19-2009 |
20090263844 | METHOD AND KIT FOR QUANTITATIVE DETERMINATION FOR SMALL, DENSE PARTICLE LOW DENSITY LIPOPROTEINS - A rapid and convenient method capable of performing fractional measurement of small, dense LDLs without pretreatment of a specimen, which is adaptable for an autoanalyzer, is provided. A method for quantitatively determining small, dense LDL cholesterol is provided, which comprises adding enzymes for cholesterol measurement to a test sample in the presence of a polyoxyethylene-polyoxypropylene copolymer or a derivative thereof, causing the polyoxyethylene-polyoxypropylene copolymer or the derivative thereof to selectively act on small, dense LDLs among lipoproteins, and then measuring the amount of cholesterol generated. | 10-22-2009 |
20090117594 | METHOD FOR MEASURING HUMAN MEGALIN - This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed. | 05-07-2009 |
20080233148 | Method of Producing Virus - It is intended to provide a safe and efficient method of producing a virus which is free from animal-origin components in the whole process from culturing adhesive cells to producing the virus on an industrial scale by the cell culture. Namely, a method of producing a virus comprising: adhering adhesive cells to a support which has a polypeptide (P) having at least one cell-adhesive minimum amino acid sequence (X) per molecule, and is free from animal-origin components; culturing the adhesive cells in a medium free from animal-origin components; subculturing the cultured adhesive cells using a cell dispersing agent free from animal-origin components; and then inoculating and proliferating a virus in the cells obtained by culturing the adhesive cells. | 09-25-2008 |